Dr. Young on Eltrombopag Added to Immunosuppression for Patients With Aplastic Anemia

Neal Young, MD
Published: Saturday, Dec 05, 2015



Neal Young, MD, senior investigator, Cell Biology Section, National Heart, Lung, and Blood Institute, National Institute of Health, discusses a study that examined the efficacy of eltrombopag when added to standard immunosuppression for patients with aplastic anemia.

In this phase II study, 92 patients were accrued. Results showed an increase in immunologic response rate, robust blood cell counts, and an improvement in survival. There was one patient death on the study, Young adds.

These results suggest that the immediate addition of eltrombopag with standard immunosuppression may salvage and expand residual hematopoietic stem cells in aplastic anemia.

<<< View more from the 2015 ASH Annual Meeting



Neal Young, MD, senior investigator, Cell Biology Section, National Heart, Lung, and Blood Institute, National Institute of Health, discusses a study that examined the efficacy of eltrombopag when added to standard immunosuppression for patients with aplastic anemia.

In this phase II study, 92 patients were accrued. Results showed an increase in immunologic response rate, robust blood cell counts, and an improvement in survival. There was one patient death on the study, Young adds.

These results suggest that the immediate addition of eltrombopag with standard immunosuppression may salvage and expand residual hematopoietic stem cells in aplastic anemia.

<<< View more from the 2015 ASH Annual Meeting


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x